IL208869A0 - Anti-cxcr4 antibodies - Google Patents

Anti-cxcr4 antibodies

Info

Publication number
IL208869A0
IL208869A0 IL208869A IL20886910A IL208869A0 IL 208869 A0 IL208869 A0 IL 208869A0 IL 208869 A IL208869 A IL 208869A IL 20886910 A IL20886910 A IL 20886910A IL 208869 A0 IL208869 A0 IL 208869A0
Authority
IL
Israel
Prior art keywords
cxcr4 antibodies
cxcr4
antibodies
Prior art date
Application number
IL208869A
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL208869A0 publication Critical patent/IL208869A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL208869A 2008-05-14 2010-10-21 Anti-cxcr4 antibodies IL208869A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5319208P 2008-05-14 2008-05-14
PCT/US2009/043063 WO2009140124A1 (en) 2008-05-14 2009-05-07 Anti-cxcr4 antibodies

Publications (1)

Publication Number Publication Date
IL208869A0 true IL208869A0 (en) 2011-01-31

Family

ID=40852496

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208869A IL208869A0 (en) 2008-05-14 2010-10-21 Anti-cxcr4 antibodies

Country Status (11)

Country Link
EP (1) EP2297206A1 (en)
JP (1) JP2011520885A (en)
KR (1) KR20100133012A (en)
CN (1) CN102027015A (en)
AU (1) AU2009246683A1 (en)
CA (1) CA2724409A1 (en)
EA (1) EA201071300A1 (en)
IL (1) IL208869A0 (en)
MX (1) MX2010012435A (en)
WO (1) WO2009140124A1 (en)
ZA (1) ZA201007955B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
MX2013004710A (en) * 2010-10-27 2013-08-29 Pf Medicament Antibodies for the treatment of hiv.
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
CA2842169A1 (en) * 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
AR087364A1 (en) 2011-07-29 2014-03-19 Pf Medicament ANTI-CXCR4 ANTIBODY AND ITS USE FOR CANCERES DETECTION AND DIANOSTIC
US10428151B2 (en) 2011-11-09 2019-10-01 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-CXCR4 antibody
TWI612059B (en) * 2013-03-15 2018-01-21 美國禮來大藥廠 Pan-elr+ cxc chemokine antibodies
BR112017026189A2 (en) 2015-06-12 2018-08-14 Bristol Myers Squibb Co cancer treatment through combined blockade of pd-1 and cxcr4 signaling pathways
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN112513079A (en) 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 anti-CXCR4 antibodies for use in the combined activation and expansion of natural killer cells for cancer immunotherapy
US20210024873A1 (en) 2018-03-27 2021-01-28 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
KR20230080460A (en) 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 How to Concentrate Protein
CN112521500B (en) * 2020-12-25 2022-06-24 暨南大学 Affinity maturation binding proteins that bind to CXCR4 and uses thereof
CN112661845B (en) * 2020-12-25 2022-06-21 暨南大学 Affinity maturation binding protein bound with CXCR4 and application thereof
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19801265C1 (en) * 1998-01-15 1999-08-12 Deutsches Krebsforsch Inhibition of CD95-independent apoptosis in AIDS
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
CA2597717C (en) * 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
BRPI0718197A2 (en) * 2006-10-02 2014-09-30 Medarex Inc ISOLATED MONOCLONAL ANTIBODY OR AN ANTIGEN-BINDING PORTION OF THE SAME, COMPOSITION, IMMUNOCATED, ISOLATED NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, HOST CELL FOR PREPARING A CIRCULAR ANCLE4 MODULES CELL, AND TO STIMULATE MOBILIZATION OF CD34 + BODY BODY CELLS FOR PERIPHERAL BLOOD IN AN INDIVIDUAL.
FR2915102B1 (en) * 2007-04-23 2014-05-16 Pf Medicament USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
AU2009246683A1 (en) 2009-11-19
KR20100133012A (en) 2010-12-20
ZA201007955B (en) 2012-04-25
CN102027015A (en) 2011-04-20
WO2009140124A1 (en) 2009-11-19
JP2011520885A (en) 2011-07-21
CA2724409A1 (en) 2009-11-19
MX2010012435A (en) 2011-05-03
EA201071300A1 (en) 2011-06-30
EP2297206A1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
ZA201007955B (en) Anti-cxcr4 antibodies
ZA201102119B (en) Improved antibody libraies
EP2241578A4 (en) Anti-cldn6 antibody
ZA201101970B (en) Multispecific antibodies
GB0708002D0 (en) Antibodies
GB0821100D0 (en) Antibodies
EP2331579A4 (en) Monoclonal antibodies
SI2200700T1 (en) Novel antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
IL212701A0 (en) Improved anti-cd19 antibodies
EP2330193A4 (en) Improved antibody molecule
PL2059533T3 (en) Multispecific antibodies
HK1136970A1 (en) Penta-specific antibody
EP2138576A4 (en) Anti-claudin-4 antibody
EP2337798A4 (en) Bsa-specific antibodies
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2172483A4 (en) ANTI-Muc17 ANTIBODY
GB0718737D0 (en) Antibodies
GB0702888D0 (en) Novel Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
EP2284538A4 (en) Biosensor
IL205073A0 (en) Anti-bst2 antibody
EP2280284A4 (en) Biosensor
EP2274332A4 (en) Anti-tnf antibody
ZA201007976B (en) Anti-pirb antibodies